SAM Holdings warns of a profit slump in FY24

Thanks to a slower-than-expected expansion in business operations.

The Singapore Institute of Advanced Medicine (SAM Holdings) expects a significant net loss for the fiscal year ended 30 June 2024 (FY 2024), due to the group’s slower-than-expected progress in its business operations, which may result in impairment to its assets.

Ahead of its preliminary FY 2024 results, the company said in a local bourse filing “there is a risk that the Group may continue reporting losses.”

The group incurred loss after tax in FY23 due to the continued development and expansion of business operations, with risks of continued reported losses.

SAM Holdings is in the process of finalising its unaudited financial results. Further details will be disclosed on or before 29 August.

Follow the link for more news on

Financial Statements

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia